| Not Yet Recruiting | BV-CHP Real-life and Biological Evidences in Patients With sALCL NCT07467317 | Fondazione Italiana Linfomi - ETS | — |
| Recruiting | Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma NCT07388563 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Exp NCT07055477 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Ly NCT07001384 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphom NCT06494371 | Ruijin Hospital | Phase 1 |
| Recruiting | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma NCT06508463 | Mayo Clinic | Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Pos NCT05770037 | Cancer Research UK | Phase 2 / Phase 3 |
| Active Not Recruiting | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T- NCT05377827 | Washington University School of Medicine | Phase 1 |
| Unknown | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types NCT05907447 | Ruijin Hospital | — |
| Completed | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies NCT05290155 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1 |
| Unknown | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD3 NCT05208853 | Zhejiang University | EARLY_Phase 1 |
| Active Not Recruiting | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma NCT04526834 | Tessa Therapeutics | Phase 1 |
| Recruiting | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing P NCT03947255 | Seagen Inc. | Phase 2 |
| Unknown | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies NCT04008394 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Completed | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancie NCT03905135 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas NCT03598998 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Terminated | Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymph NCT03590574 | Autolus Limited | Phase 1 / Phase 2 |
| Completed | Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma NCT03534180 | City of Hope Medical Center | Phase 2 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms NCT03493451 | BeiGene | Phase 2 |
| Withdrawn | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large NCT03205891 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas NCT03383965 | Immune Cell, Inc. | Phase 1 |
| Completed | Vinorelbine for Recurrent ALCL-2017 NCT03443128 | Children's Cancer Group, China | Phase 2 |
| Completed | Vinorelbine for Recurrent ACLC NCT03397953 | Children's Cancer Group, China | Phase 2 |
| Terminated | Ceritinib Rare Indications Study in ALK+ Tumors NCT02465528 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715 | Mayo Clinic | N/A |
| Unknown | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT02232516 | Northwestern University | Phase 2 |
| Withdrawn | Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgki NCT01769911 | Fred Hutchinson Cancer Center | N/A |
| Completed | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lym NCT02168140 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Completed | A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lym NCT01950364 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Completed | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma NCT01943682 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Completed | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diag NCT01793233 | Children's Oncology Group | — |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Active Not Recruiting | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409 | Mayo Clinic | N/A |
| Terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 | Northwestern University | Phase 1 / Phase 2 |
| Terminated | Ipilimumab and Local Radiation for Selected Solid Tumors NCT01769222 | Stanford University | Phase 1 |
| Completed | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients NCT01777152 | Seagen Inc. | Phase 3 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL NCT01686165 | University of Arizona | Phase 2 |
| Completed | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma NCT01657331 | Columbia University | Phase 1 / Phase 2 |
| Terminated | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic L NCT01419795 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-C NCT01567709 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma NCT01466881 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma NCT01336933 | University of Nebraska | Phase 2 |
| Completed | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma NCT01326702 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01336920 | University of Nebraska | Phase 1 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma NCT01261247 | Mayo Clinic | Phase 2 |
| Completed | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT01075321 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma NCT01258998 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Completed | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma NCT01129180 | Pierluigi Porcu | Phase 1 |
| Terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin L NCT01116154 | City of Hope Medical Center | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Withdrawn | Denileukine Diftitox for Relapsed ALCL NCT00801918 | Columbia University | Phase 2 |
| Completed | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surg NCT00608361 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of MLN8237 in Participants With Advanced Hematological Malignancies NCT00697346 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Completed | Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma NCT00644189 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Terminated | Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas NCT00704691 | University of Alabama at Birmingham | EARLY_Phase 1 |
| Completed | Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT00720135 | City of Hope Medical Center | Phase 1 |
| Completed | Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma NCT00606645 | Xencor, Inc. | Phase 1 |
| Completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory NCT00601718 | University of Washington | Phase 1 / Phase 2 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell NCT00354107 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma NCT00365274 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00293345 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid NCT00354185 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With NCT00310128 | AIDS Malignancy Consortium | Phase 2 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma NCT00278382 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma NCT00131937 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hemat NCT00103272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, NCT00117988 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas NCT00089271 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma NCT00082888 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma NCT00079755 | Seagen Inc. | Phase 2 |
| Completed | Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00077155 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Trea NCT00072514 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma NCT00058019 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma NCT00016094 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | 506U78 in Treating Patients With Lymphoma NCT00005080 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymph NCT00004241 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymph NCT01678443 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treati NCT00073918 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma NCT00003970 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lympho NCT00001337 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |